Radiotherapy in patients with inoperable NSCLC during therapy with checkpoint inhibitor
Authors: A.V. Kirillov, I.R. Agranov, M.A. Krasavina, E.V. Artemieva, A.S. Zhabina, S.A. Belukhin, M.L. Makarkina, E.O. Elsakova, A.P. Oganesian, V.A. Heinstein, K.K. Lebedev, Ya.V. Belysheva, C.A. Guseinova, T.M. Sharabura, V.A. Chubenko, A.V. Myslik, N.V. Levchenko, A.A. Bogdanov, N.M. Volkov, V.V. Egorenkov, F.V. Moiseenko, V.M. Moiseyenko
DOI: https://www.doi.org/10.31917/2504362
Purpose: to evaluate the effectiveness of radiation therapy used in oligometastatic syndrome recently in NSCLC against
the background of systemic therapy with the inclusion of immune checkpoint inhibitors.
Methods: in a retrospective analysis of 117 patients, 17 received RT before progression on checkpoint inhibitors,
10 patients received local treatment before systemic therapy, and 7 patients received it while on systemic therapy.
Symptomatic lesions in the brain, as well as metastases in the lungs and bones, were treated with RT.
Results: the time to progression in the local treatment group was 15.6 months [95% CI 9.8-21.3] versus 11.2 months [95%
CI 6.1-16.2] in the group without local treatment (p=0.476). In turn, the overall survival was 17.2 months [95% CI 9.3-25.1]
in the group with local treatment versus 16.9 months [95% CI 12.8-21.1] in patients without local treatment (p=0.558).
Conclusion: the use of radiation therapy for oligometastatic progression in the background of the 1st line with the
inclusion of immunotherapy made it possible to increase the overall life expectancy of patients.